DFTX · NASDAQ · STOCK
Definium Therapeutics (DFTX) Stock Analysis
$38.08
52W $12.88 – $49.20
57/100
$5.06B
-11.1
2.24
Is DFTX Bullish or Bearish?
Mixed.
Innellis AI committee rates Definium Therapeutics, Inc. (DFTX) Watch with a composite score of 57/100
, based on 6 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.20 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.80 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+1.00 across 1 articles, 14d). Growth Analyst remains cautious — 4 consecutive earnings misses -- execution concerns. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+1.00 across 1 articles, 14d) — News
Bear Case
- Price-to-book of 4.0x prices in significant intangible value — Value
- ROE of only -85.2% -- cheap may mean cheap for a reason — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 27 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 77%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.0x prices in significant intangible value
Growth Analyst
bearish
28
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 27 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bullish
62
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock
− Bollinger bandwidth of 26.0% signals elevated volatility
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
90
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+1.00 across 1 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 56.8 to 56.8.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
26.9
Oversold
MACD Histogram
-0.861
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$19.34
Resistance
$49.16
Bollinger %B
0.09
Inside Bands
Price vs Moving Averages
EMA 9
$40.15
Below
EMA 21
$41.76
Below
EMA 50
$40.48
Below
EMA 200
$28.14
Above
Fundamental Analysis
Valuation
84
Growth
6
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-11.1×
P/B Ratio
4.59×
PEG Ratio
0.15
Dividend Yield
0.00%
52W High
$49.20
52W Low
$12.88
Quality & Growth
ROE
-5530.5%
ROA
-4176.2%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.04
AI Fundamental Assessment
P/E ratio of -11.1 (inexpensive relative to a 15-40x range); Price-to-book of 4.6x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -55.3%; Return on assets of -41.8%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 6.95 (healthy short-term liquidity); Debt-to-equity of 0.04; Free cash flow per share is negative (-1.51); Most recent quarter missed estimates by 158.2%; 4 consecutive earnings misses; EPS growth decelerating (-42.0% -> -102.8% QoQ); Analyst estimates falling over recent quarters
Get the Full DFTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →